Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Hypertension Drug Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Hypertension Drug Industry
  • 1.7 COVID-19 Impact: Hypertension Drug Market Trends

    • 2 Global Hypertension Drug Quarterly Market Size Analysis

    • 2.1 Hypertension Drug Business Impact Assessment - COVID-19
      • 2.1.1 Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Hypertension Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Hypertension Drug Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Hypertension Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Hypertension Drug Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Hypertension Drug Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Hypertension Drug Market
    • 3.5 Key Manufacturers Hypertension Drug Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Hypertension Drug Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Calcium Channel Blockers
      • 1.4.2 Diuretics
      • 1.4.3 Beta Blockers Vasodilators
      • 1.4.4 Angiotensin Converting Enzyme Inhibitors
      • 1.4.5 Alpha Blockers
      • 1.4.6 Angiotensin Receptor Blockers
      • 1.4.7 Renin Inhibitors
    • 4.2 By Type, Global Hypertension Drug Market Size, 2019-2021
      • 4.2.1 By Type, Global Hypertension Drug Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Hypertension Drug Price, 2020-2021

    5 Impact of Covid-19 on Hypertension Drug Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospital
      • 5.5.2 Private clinic
      • 5.5.3 Others
    • 5.2 By Application, Global Hypertension Drug Market Size, 2019-2021
      • 5.2.1 By Application, Global Hypertension Drug Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Hypertension Drug Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Lupin Limited
      • 7.1.1 Lupin Limited Business Overview
      • 7.1.2 Lupin Limited Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.1.3 Lupin Limited Hypertension Drug Product Introduction
      • 7.1.4 Lupin Limited Response to COVID-19 and Related Developments
    • 7.2 Novartis AG
      • 7.2.1 Novartis AG Business Overview
      • 7.2.2 Novartis AG Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.2.3 Novartis AG Hypertension Drug Product Introduction
      • 7.2.4 Novartis AG Response to COVID-19 and Related Developments
    • 7.3 Daiichi - Sankyo
      • 7.3.1 Daiichi - Sankyo Business Overview
      • 7.3.2 Daiichi - Sankyo Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.3.3 Daiichi - Sankyo Hypertension Drug Product Introduction
      • 7.3.4 Daiichi - Sankyo Response to COVID-19 and Related Developments
    • 7.4 Pfizer Inc
      • 7.4.1 Pfizer Inc Business Overview
      • 7.4.2 Pfizer Inc Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.4.3 Pfizer Inc Hypertension Drug Product Introduction
      • 7.4.4 Pfizer Inc Response to COVID-19 and Related Developments
    • 7.5 Ranbaxy Laboratories Limited
      • 7.5.1 Ranbaxy Laboratories Limited Business Overview
      • 7.5.2 Ranbaxy Laboratories Limited Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.5.3 Ranbaxy Laboratories Limited Hypertension Drug Product Introduction
      • 7.5.4 Ranbaxy Laboratories Limited Response to COVID-19 and Related Developments
    • 7.6 Sanofi S.A
      • 7.6.1 Sanofi S.A Business Overview
      • 7.6.2 Sanofi S.A Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.6.3 Sanofi S.A Hypertension Drug Product Introduction
      • 7.6.4 Sanofi S.A Response to COVID-19 and Related Developments
    • 7.7 AstraZeneca Plc
      • 7.7.1 AstraZeneca Plc Business Overview
      • 7.7.2 AstraZeneca Plc Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.7.3 AstraZeneca Plc Hypertension Drug Product Introduction
      • 7.7.4 AstraZeneca Plc Response to COVID-19 and Related Developments
    • 7.8 Johnson & Johnson Ltd
      • 7.8.1 Johnson & Johnson Ltd Business Overview
      • 7.8.2 Johnson & Johnson Ltd Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.8.3 Johnson & Johnson Ltd Hypertension Drug Product Introduction
      • 7.8.4 Johnson & Johnson Ltd Response to COVID-19 and Related Developments
    • 7.9 Boehringer Ingelheim
      • 7.9.1 Boehringer Ingelheim Business Overview
      • 7.9.2 Boehringer Ingelheim Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.9.3 Boehringer Ingelheim Hypertension Drug Product Introduction
      • 7.9.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
    • 7.10 Merck & Co.
      • 7.10.1 Merck & Co. Business Overview
      • 7.10.2 Merck & Co. Hypertension Drug Quarterly Production and Revenue, 2020
      • 7.10.3 Merck & Co. Hypertension Drug Product Introduction
      • 7.10.4 Merck & Co. Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Hypertension Drug Supply Chain Analysis
      • 8.1.1 Hypertension Drug Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Hypertension Drug Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Hypertension Drug Distribution Channels
      • 8.2.2 Covid-19 Impact on Hypertension Drug Distribution Channels
      • 8.2.3 Hypertension Drug Distributors
    • 8.3 Hypertension Drug Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Hypertension Drug, including the following market information:
      Global Hypertension Drug Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Hypertension Drug Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Hypertension Drug Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Hypertension Drug Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

      Key market players
      Major competitors identified in this market include Lupin Limited, Novartis AG, Daiichi - Sankyo, Pfizer Inc, Ranbaxy Laboratories Limited, Sanofi S.A, AstraZeneca Plc, Johnson & Johnson Ltd, Boehringer Ingelheim, Merck & Co., etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Calcium Channel Blockers
      Diuretics
      Beta Blockers Vasodilators
      Angiotensin Converting Enzyme Inhibitors
      Alpha Blockers
      Angiotensin Receptor Blockers
      Renin Inhibitors

      Based on the Application:
      Hospital
      Private clinic
      Others

      Buy now